# mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line

Source: https://onco.cc/trials/nct07062536/  
OnCo record `nct07062536` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of oxaliplatin, leucovorin, FOLFOX and other drugs in gallbladder cancer and other biliary tract cancers, run by Seoul National University Bundang Hospital, now recruiting.

## Summary

mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line is a phase 2, randomised interventional study registered as NCT07062536 by Seoul National University Bundang Hospital, with a registry enrolment figure of 130 participants, started 2025-08-27 and due to reach its primary completion in 2027-04-01. Interventions recorded: Oxaliplatin, 5FU, leucovorin, Oxaliplatin, 5FU, leucovorin/Irinotecan , 5FU, leucovorin,. Conditions listed: Biliary Cancer Metastatic. Gallbladder cancer is named in the registry entry: "2. Diagnosed with biliary tract cancer, including intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, gallbladder cancer, or ampulla of Vater cancer.". Sites: South Korea. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT07062536
- Phase: 2
- Setting: A Randomized Phase II Clinical Trial to Evaluate the Efficacy Alternating mFOLFOX/mFOLFIRI Chemotherapy Regimen as a Second-line Treatment for Advanced Biliary Tract Cancer
- Sponsor: Seoul National University Bundang Hospital
- Enrolled: 130

## Sources

- ClinicalTrials.gov NCT07062536: https://clinicaltrials.gov/study/NCT07062536

## Connected records

- cancers: [Ampullary cancer (ampulla of Vater)](https://onco.cc/cancers/ampullary/), [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Extrahepatic cholangiocarcinoma (perihilar and distal)](https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Irinotecan (and liposomal irinotecan)](https://onco.cc/drugs/irinotecan/), [Leucovorin (folinic acid)](https://onco.cc/drugs/leucovorin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct07062536.json